Taysha Gene Therapies (NASDAQ:TSHA) Earns "Buy" Rating from Needham & Company LLC

Key Points

• Needham & Company LLC has reaffirmed a "buy" rating for Taysha Gene Therapies (NASDAQ:TSHA), with a price target of $10.00, indicating a potential upside of 96.85% from the current stock price.
• The company's stock recently opened at $5.08 and is currently trading down by 4.9% despite a recent average rating of "Moderate Buy" from nine analysts.
• Taysha Gene Therapies reported a quarterly revenue of $1.99 million, exceeding expectations, but missed EPS estimates with a reported loss of ($0.09).

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report)'s stock had its "buy" rating reaffirmed by Needham & Company LLC in a research report issued on Friday,Benzinga reports. They currently have a $10.00 price target on the stock. Needham & Company LLC's target price would suggest a potential upside of 96.85% from the company's current price.

Other analysts also recently issued reports about the company. Wells Fargo & Company upped their price objective on Taysha Gene Therapies from $7.50 to $8.00 and gave the company an "overweight" rating in a research note on Wednesday, August 13th. Bank of America began coverage on Taysha Gene Therapies in a research note on Friday, July 11th. They set a "buy" rating and a $8.00 target price for the company. Chardan Capital reissued a "buy" rating and set a $12.00 target price on shares of Taysha Gene Therapies in a research note on Friday. Weiss Ratings reissued a "sell (d-)" rating on shares of Taysha Gene Therapies in a research note on Wednesday, October 8th. Finally, Robert W. Baird increased their target price on Taysha Gene Therapies from $7.00 to $12.00 and gave the stock an "outperform" rating in a research note on Thursday, October 2nd. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Taysha Gene Therapies has an average rating of "Moderate Buy" and a consensus target price of $9.25.

Taysha Gene Therapies Stock Down 4.9%

TSHA opened at $5.08 on Friday. The business has a 50 day moving average price of $3.43 and a two-hundred day moving average price of $2.67. The company has a quick ratio of 12.48, a current ratio of 12.48 and a debt-to-equity ratio of 0.17. The company has a market cap of $1.39 billion, a PE ratio of -14.94 and a beta of 0.99. Taysha Gene Therapies has a 52 week low of $1.05 and a 52 week high of $5.51.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The company had revenue of $1.99 million for the quarter, compared to analysts' expectations of $1.61 million. Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%. As a group, research analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Buying and Selling at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $3.23, for a total transaction of $646,000.00. Following the sale, the insider owned 1,006,439 shares in the company, valued at approximately $3,250,797.97. This represents a 16.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 3.78% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of large investors have recently bought and sold shares of TSHA. Marex Group plc acquired a new stake in Taysha Gene Therapies during the 2nd quarter valued at $29,000. E Fund Management Co. Ltd. acquired a new stake in Taysha Gene Therapies during the 2nd quarter valued at $31,000. ST Germain D J Co. Inc. lifted its stake in shares of Taysha Gene Therapies by 81.8% during the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company's stock worth $32,000 after purchasing an additional 4,333 shares during the period. May Hill Capital LLC purchased a new position in shares of Taysha Gene Therapies during the 2nd quarter worth $37,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Taysha Gene Therapies by 156.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company's stock worth $41,000 after purchasing an additional 10,742 shares during the period. Institutional investors and hedge funds own 77.70% of the company's stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.